SG47453A1 - Dimer of molecular variant of apolipoprotein and processes for the production thereof - Google Patents

Dimer of molecular variant of apolipoprotein and processes for the production thereof

Info

Publication number
SG47453A1
SG47453A1 SG1996001800A SG1996001800A SG47453A1 SG 47453 A1 SG47453 A1 SG 47453A1 SG 1996001800 A SG1996001800 A SG 1996001800A SG 1996001800 A SG1996001800 A SG 1996001800A SG 47453 A1 SG47453 A1 SG 47453A1
Authority
SG
Singapore
Prior art keywords
dimer
apolipoprotein
pct
apo
processes
Prior art date
Application number
SG1996001800A
Other languages
English (en)
Inventor
Cesare Cirtori
Guido Franceschini
Lars Abrahmsen
Erik Holmgren
Mats Lake
Bjorn Nilsson
Joanna Chnielewska
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of SG47453A1 publication Critical patent/SG47453A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG1996001800A 1991-12-13 1992-12-11 Dimer of molecular variant of apolipoprotein and processes for the production thereof SG47453A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9103701A SE9103701D0 (sv) 1991-12-13 1991-12-13 Apolipoprotein

Publications (1)

Publication Number Publication Date
SG47453A1 true SG47453A1 (en) 1998-04-17

Family

ID=20384608

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996001800A SG47453A1 (en) 1991-12-13 1992-12-11 Dimer of molecular variant of apolipoprotein and processes for the production thereof

Country Status (28)

Country Link
US (2) US5876968A (pl)
EP (1) EP0571602B1 (pl)
JP (1) JPH07502892A (pl)
AT (1) ATE242269T1 (pl)
AU (2) AU3175593A (pl)
BG (1) BG61451B1 (pl)
BR (1) BR9205640A (pl)
CA (1) CA2103996C (pl)
CZ (1) CZ289879B6 (pl)
DE (1) DE69233092T2 (pl)
DK (1) DK0571602T3 (pl)
EE (1) EE03058B1 (pl)
ES (1) ES2199939T3 (pl)
FI (1) FI115771B (pl)
HU (2) HU217203B (pl)
IL (1) IL103956A (pl)
MX (1) MX9207224A (pl)
NO (1) NO315076B1 (pl)
NZ (2) NZ246223A (pl)
PL (3) PL172168B1 (pl)
PT (1) PT571602E (pl)
RO (1) RO115636B1 (pl)
RU (1) RU2134696C1 (pl)
SE (1) SE9103701D0 (pl)
SG (1) SG47453A1 (pl)
SK (1) SK86893A3 (pl)
WO (1) WO1993012143A1 (pl)
ZA (1) ZA928989B (pl)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US6258596B1 (en) 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
FR2734568B1 (fr) * 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) * 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US20020064820A1 (en) * 2000-03-13 2002-05-30 Jean-Michel Dayer Apo-A-I regulation of T-cell signaling
CA2407083A1 (en) 2000-04-21 2001-11-01 Amgen Inc. Apo-ai/aii peptide derivatives
BRPI0003386B8 (pt) * 2000-08-08 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
EP2343317A1 (en) * 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
US7217785B2 (en) * 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
MXPA04002848A (es) * 2001-09-28 2005-06-06 Esperion Therapeutics Inc Prevencion y tratamiento de restenosis por administracion local de medicamento.
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
EP1461028A4 (en) * 2001-12-07 2007-07-25 Univ California TREATMENT OF MACULAR DEGENERATION WITH AGING
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
US20100204103A1 (en) * 2002-05-08 2010-08-12 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
CN1668645A (zh) * 2002-05-17 2005-09-14 埃斯佩里安医疗公司 治疗缺血再灌注的方法和组合物
CA2486127C (en) 2002-05-17 2014-03-11 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
WO2005051413A2 (en) * 2003-11-26 2005-06-09 Novartis Ag Disease associated genes
AU2004299486B2 (en) * 2003-12-15 2011-05-19 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
WO2005097206A2 (en) * 2004-04-06 2005-10-20 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US9487575B2 (en) * 2004-07-14 2016-11-08 The Regents Of The University Of California Compositions and methods for treatment of gynecologic cancers
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
JP2008539235A (ja) 2005-04-29 2008-11-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 炎症反応によって特徴付けられる病状を処置するためのペプチドおよびペプチド模倣物
WO2007000924A1 (ja) * 2005-06-28 2007-01-04 Osaka University プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法
KR100719389B1 (ko) 2005-10-18 2007-05-17 주식회사 녹십자 인간혈장으로부터 아포리포단백질 ａ-ｉ을 분리 정제하는방법
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
AU2007284801A1 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
EP2057270A1 (en) * 2006-08-10 2009-05-13 Plantechno SRL In-plant production of dimeric and/or oligomeric (comprising three or more units) forms of human apo a-1 protein muteins
US8541236B2 (en) * 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
EP2195331B1 (en) 2007-08-28 2013-11-20 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US20100212030A1 (en) * 2007-10-19 2010-08-19 Pronota N.V. Use of n-terminal and c-terminal proteomics technology to enhance protein therapeutics and diagnostics
EP2212351B1 (en) 2007-10-23 2017-09-13 The Cleveland Clinic Foundation Oxidant resistant apolipoprotein a-1 and mimetic peptides
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
MX338780B (es) 2008-11-10 2016-05-02 Alnylam Pharmaceuticals Inc Lipidos y composiciones novedosas para el suministro de terapeuticos.
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
CA2754043A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
CN102421417B (zh) 2009-05-05 2016-03-02 阿尔尼拉姆医药品有限公司 脂质组合物
MX2011013320A (es) 2009-06-10 2012-02-28 Alnylam Pharmaceuticals Inc Formulacion mejorada de lipido.
AP2015008874A0 (en) 2009-08-14 2015-11-30 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
WO2011071860A2 (en) 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
CA2778872C (en) * 2009-12-14 2015-06-02 Scil Proteins Gmbh A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands
AU2010330814B2 (en) 2009-12-18 2017-01-12 Acuitas Therapeutics Inc. Methods and compositions for delivery of nucleic acids
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143362A1 (en) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
NZ605079A (en) 2010-06-03 2015-08-28 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US20130142760A1 (en) 2010-08-18 2013-06-06 Cedars-Sinai Medical Center Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer
CN110123830A (zh) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
EP3202760B1 (en) 2011-01-11 2019-08-21 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
EP2767546B1 (en) 2011-02-07 2018-10-17 Cerenis Therapeutics Holding SA Lipoprotein complexes and manufacturing and uses therof
EP2721152B1 (en) 2011-06-15 2019-03-27 Navigo Proteins GmbH Dimeric binding proteins based on modified ubiquitins
CA2838070A1 (en) 2011-08-25 2013-02-28 F. Hoffmann-La Roche Ag Shortened tetranectin-apolipoprotein a-i fusion protein, a lipid particle containing it, and uses thereof
US9701623B2 (en) 2011-09-27 2017-07-11 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
US9610324B2 (en) 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
JP2017515893A (ja) 2014-05-02 2017-06-15 セレニス セラピューティクス ホールディング エスアー Ｈｄｌ治療マーカー
EP3189069A4 (en) 2014-07-31 2018-03-07 UAB Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
WO2016124702A1 (en) 2015-02-06 2016-08-11 Scil Proteins Gmbh Novel egfr binding proteins
DK3322721T3 (da) 2015-07-16 2022-03-14 Navigo Proteins Gmbh Nye immunglobulin-bindende proteiner og deres anvendelse i affinitetsoprensning
JP2018520675A (ja) 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
CA3022751A1 (en) 2016-05-04 2017-11-09 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
CN117736281A (zh) 2016-08-11 2024-03-22 瑞普利金公司 用于亲和色谱的碱性稳定性fc结合蛋白
EP3668549B1 (en) 2017-08-10 2024-05-15 Abionyx Pharma SA Apomers
TW201919712A (zh) 2017-08-10 2019-06-01 法商塞勒尼斯醫療控股公司 運送子(cargomers)
EP3706804B1 (en) 2017-11-07 2022-02-23 Navigo Proteins GmbH Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
CN115427064A (zh) 2020-04-16 2022-12-02 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗急性病况的方法
AU2021354095A1 (en) 2020-10-01 2023-06-08 Abionyx Pharma Sa Compositions comprising lipid binding protein-based complexes for use for treating eye diseases
MX2023012223A (es) 2021-04-15 2023-10-26 Abionyx Pharma Sa Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos.
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein

Also Published As

Publication number Publication date
ES2199939T3 (es) 2004-03-01
BG98036A (bg) 1994-05-27
US5876968A (en) 1999-03-02
MX9207224A (es) 1993-06-01
IL103956A0 (en) 1993-05-13
PL300262A1 (en) 1994-03-07
FI933557A0 (fi) 1993-08-12
NZ280516A (en) 1997-06-24
SE9103701D0 (sv) 1991-12-13
EE03058B1 (et) 1997-12-15
CA2103996C (en) 2007-01-16
JPH07502892A (ja) 1995-03-30
SK86893A3 (en) 1994-04-06
BG61451B1 (en) 1997-08-29
DE69233092D1 (de) 2003-07-10
DK0571602T3 (da) 2003-10-06
NO315076B1 (no) 2003-07-07
RO115636B1 (ro) 2000-04-28
NO932866L (no) 1993-08-12
CA2103996A1 (en) 1993-06-14
CZ289879B6 (cs) 2002-04-17
ZA928989B (en) 1993-05-17
PL172168B1 (pl) 1997-08-29
HU211667A9 (en) 1995-12-28
PT571602E (pt) 2003-10-31
WO1993012143A1 (en) 1993-06-24
DE69233092T2 (de) 2004-07-08
PL172544B1 (pl) 1997-10-31
US6617134B1 (en) 2003-09-09
HU217203B (hu) 1999-12-28
AU3175593A (en) 1993-07-19
RU2134696C1 (ru) 1999-08-20
BR9205640A (pt) 1994-05-03
HUT70270A (en) 1995-09-28
HU9302344D0 (en) 1994-01-28
CZ158993A3 (en) 1994-07-13
AU703283B2 (en) 1999-03-25
NZ246223A (en) 1996-06-25
AU5947396A (en) 1996-10-31
PL171907B1 (pl) 1997-06-30
FI115771B (fi) 2005-07-15
EP0571602A1 (en) 1993-12-01
NO932866D0 (no) 1993-08-12
FI933557A (fi) 1993-08-12
ATE242269T1 (de) 2003-06-15
EP0571602B1 (en) 2003-06-04
IL103956A (en) 1998-09-24

Similar Documents

Publication Publication Date Title
SG47453A1 (en) Dimer of molecular variant of apolipoprotein and processes for the production thereof
RU93054168A (ru) Димер молекулярного варианта аро-липопротеина, способ его получения, фармацевтическая композиция на его основе
IL126038A0 (en) Novel benzothiepines and derivatives thereof and pharmaceutical compositions comprising them
WO1998040375A3 (en) COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS
ATE73657T1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose.
NO962664D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
CA2040865A1 (en) Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
EP0719791A2 (en) Medicaments for the treatment of restenosis and arterial sclerosis
KR0148213B1 (en) Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same
ATE127846T1 (de) Herstellung von hv/hb copolymer.
ES2171465T3 (es) Inhibidor de la esterasa de c1 para reducir lesiones de miocardio durante un infarto de miocardio agudo.
ATE133334T1 (de) Gammalinolensäure zur herstellung eines medikaments zur verhinderung von wiederverschluss von arterien
ZA954826B (en) New hydrazino and hydroxyamino-14beta-hydroxyandrostane derivatives active on the cardiovascular system processes for their preparation and pharmaceutical compositions containing same
WO1994002107A3 (en) Method and medicament for inhibiting neutrophil elastase and cathepsin g
AU6394698A (en) Oxiran carboxylic acids for the treatment of diabetes
WO1994004017A3 (en) New method of treatment
FI885673A0 (fi) Termotropiska aromatiska vaetskekristallpolyestrar.
MX9703534A (es) Cromanos sustituidos con sulfonamida, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que los contiene.